darkMatter®

Genetics, longevity and mycology, read carefully.

Your genome is a lifelong document, and the science that reads it keeps moving. We write down what the evidence supports, and what it does not yet.

WHAT DARKMATTER IS

darkMatter is a biotech company working on the damage that ages us.

We develop our own technology, back founders building theirs, and publish what the science supports.

Three subjects, one question underneath

01 — Genetics

What your genome actually says

Risk scores, rare variants, inheritance. A result places you in a population; it does not predict your life.

02 — Longevity

What holds up over decades

Interventions, biomarkers and evidence quality: what decades of follow-up support, and what is still only plausible.

03 — Mycology

The kingdom we keep underestimating

Fungal genomes, symbiosis and metabolism: where much of what we know about cellular ageing was first observed.

The science

How does reading a whole genome work?

How a whole genome actually gets read, explained plainly. It is the science we keep returning to.

01

A cheek swab

Cells from inside the cheek carry the same complete instruction set as every other cell. Thirty seconds is enough.

02

Read at 30× depth

Each position is read about thirty independent times. That redundancy is what separates a real variant from an error.

03

Interpreted

Six billion letters become a few million differences from the reference, then the few hundred anyone currently knows how to act on.

04

Read again later

The sequence does not change; its meaning does. Re-interpretation is the part that makes one sample worth keeping.

6B
Base pairs in a human genome: the complete text, not a summary of it
30×
Average depth of coverage, the standard research institutions work at
0.02%
Roughly what a consumer chip test reads of that same text
Open to everyone

Read each piece first

Leave your address and every new piece reaches you the day it publishes. That is the whole of it: no fees, no gate, no selling.

Investments

darkMatter acquired the management and general partner of the MarsBio Fund in 2025 and now manages a portfolio of 13 companies building at the frontier of biology.

The full portfolio, our thesis and how to pitch us →
FAQ

Fair questions, answered straight

Including the one about whether you can buy anything yet.

It always starts with you.

Six billion letters, already written. We are learning to read them properly, and publishing as we go.